Concorde Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Concorde Asset Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,745	Closed	-$205K	–	172
2021 Q3	$205K	Sell	2,745 -219	-7%	-$18.4K	0.12%	183
2021 Q2	$275K	Buy	2,964 +163	+6%	+$13.9K	0.15%	146
2021 Q1	$249K	Buy	+2,801	New	+$278K	0.14%	171

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Concorde Asset Management's ARKG Position: Q4 2021 in Review

Concorde Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 2,745 shares — an estimated $205K sold.

Concorde Asset Management first reported a position in ARKG in Q1 2021 and held it in 3 quarters. The position peaked at $275K in Q2 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

Concorde Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
Concorde Asset Management sold 2,745 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $205K.
Concorde Asset Management first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 3 quarters.
Concorde Asset Management's ARK Genomic Revolution ETF position peaked at $275K in Q2 2021.
460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Concorde Asset Management's 13F filing for Q4 2021, filed 2 Feb 2022.